Phenotypes of mutant mice. Peritoneal macrophages from each strain were treated with each specific inducer as indicated. After 4 h of incubation, supernatants were collected and assayed in duplicate for TNF concentrations using the L929 bioassay (Poc in A–H, Lkd in J and K, and Int in M–O). Values represent mean ± SEM (n = 6 mice or more). (I and L) Macrophages from WT, Poc (I), or Lkd (L) mice were pretreated with IFN-γ (10 units/ml) for 4 h. Cells were washed with medium once and treated with TLR ligands as indicated for another 4 h. The supernatants were collected, and the concentration of type I IFN was assayed by using a L929-ISRE-Luc-based bioassay. Similar results were observed in three independent experiments.

The α_E-helices of TIR domains are not involved in receptor:adapter interactions. (A–C) A total of 100 ng (A) or 10 ng (B and C) of vector control or the indicated TLR constructs were transfected together with 50 ng of pNiFty-luc into HEK-293 cells. After 24 h cells were left untreated or treated with ligands for 4 h and then harvested and assayed for luciferase activity. (D) HEK-293 cells were transfected with HA-tagged MyD88^FW/AA and with M2-tagged TLRs. After 36 h, cells were left untreated or treated with MALP2 (for TLR2 transfectants) or lipid A (for TLR4 transfectants) for 10 min. The cells were then lysed and immunoprecipitated with M2-Flag. Immunoblotting was then performed with antibody against the HA tag on MyD88^FW/AA. The expression of transfected MyD88^FW/AA and TLRs was examined in the whole-cell extracts (WCE). (E and F) Proposed TIR domain interactions based on docking studies. (E) Face-to-face interaction mode mediating receptor:adapter binding. TLR2 is shown in blue, and MyD88 is shown in yellow. Individual amino acids and motifs are indicated by arrows in colors corresponding to the color of each protein. The critical P residue of each BB loop is shown in red, and the critical V or I residue of the Poc site is shown in green. (F) Back-to-back interaction mode mediating TIR domain oligomerization. Blue and yellow ribbons may now be taken to represent TIR domains of two different MyD88 proteins or two different TLR2 molecules after ligand stimulation. The interaction is mediated by the C-terminal α-helices (α_E) in an antiparallel fashion.

Effects of the Poc and Lkd mutations in vivo and ex vivo. (A) The Poc mutation confers sensitivity to MALP-2-induced lethal toxicity. Wild-type, Poc, and MyD88-deficient mice were injected i.p. with 3 μg of MALP-2 and 20 mg of d-galactosamine. Survival was monitored over a period of 3 days (no change was observed after 48 h), and the data are expressed as a Kaplan–Meier plot (P < 0.0001). (B and C) The Poc allele of MyD88 supports resistance to skin infection caused by S. pyogenes. Mice were each injected s.c. with S. pyogenes (5 × 10⁵ colony-forming units). During a 5-day period, bacterial growth was monitored daily with the Xenogen IVIS imaging system. (C) Luminescence (photons emitted per second) was measured in a defined and constant region of interest. Data are shown as means ± SEM0 (n ≥ 4 mice). (D and E) Poc mice are hypersusceptible to L. monocytogenes infection. Mice were injected i.v. with L. monocytogenes as described in Materials and Methods. Bioluminescence imaging was performed by using the IVIS Imaging System. The survival of these mice was monitored during a 7-day period. P values refer to comparison with wild type (E). (F and G) Poc mice are hypersusceptible to mouse CMV infection. (F) Viral titers, expressed as log plaque-forming units per spleen, were determined in mice 5 days after i.p. inoculation with 5 × 10⁵ plaque-forming units of mouse CMV. (G) Blood was collected 36 h after infection, and the concentrations of type I IFN in serum were analyzed by ELISA. (H) Macrophages from Poc or MyD88^−/− mice were treated with either MALP-2 or Pam₂CSK₄ for the indicated times. Cells were lysed and analyzed by immunoblotting with antibodies indicated. (I) MyD88^Poc interacts with TLR2 after MALP-2 treatment. HEK-293 cells were transiently transfected with M2-Flag-tagged TLR2 and HA-tagged WT-MyD88 or MyD88^Poc and treated with Pam₃CSK₄ or MALP-2 for the indicated times. Cells were lysed and immunoprecipitated with M2-Flag followed by immunoblotting with antibody against the HA. The expression of transfected MyD88 and TLR2 was examined in the whole-cell extracts (WCE).

Diacylated lipopeptides activate TLR2 in a unique way. (A–C) Ten nanograms of vector control (pCMV-Flag), TLR2-WT, or TLR2^Poc was transfected together with 50 ng of pNiFty-luc into HEK-293 cells. After 24 h, cells were left untreated or treated with TLR2 ligands at different concentrations as indicated. Four hours later, luciferase reporter assay was performed. (D) HEK-293 cells were transfected with 50 ng of pNiFty-luc construct together with indicated amount of MD-2 (0, 20, and 50 ng) and TLR4-WT or TLR4^Poc (0, 20, and 50 ng). After 24 h, cells were harvested and analyzed by luciferase reporter assay. Cell extracts were also used to examine the expression of TLR4 and MD2 by immunoblotting (Inset). (E and F) HEK-293 cells were transfected with 50 ng of pNiFty-luc and 50 ng of each construct as indicated. A luciferase reporter assay was performed after 24 h. Cell extracts were used to examine the expression of the wild-type and mutant TLR2 variants by using antibody against M2-Flag (Inset). (G and H) MEFs derived from Tlr2^−/− (G) or MyD88^−/− (H) mice were transfected with 20 ng of pNiFty-luc and 20 ng of different TLR2 or MyD88 expression vectors as indicated. Twenty-four hours after transfection, cells were left untreated or treated with TLR2 ligands as indicated for 6 h and analyzed with luciferase assay. Cell extracts were also used to examine the expression of the wild-type and mutant MyD88 by using antibody against the HA tag (Inset).